Naomi Matsuo
Overview
Explore the profile of Naomi Matsuo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
96
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Furuya F, Fujita Y, Matsuo N, Minamino H, Oguri Y, Isomura N, et al.
EBioMedicine
. 2022 Nov;
86:104342.
PMID: 36423374
Background: Sodium glucose co-transporter 2 (SGLT2) inhibitors are anti-diabetic drugs for type 2 diabetes that lower blood glucose levels and body weight. It is of special interest that SGLT2 inhibitors...
2.
Miyoshi T, Miyashita H, Matsuo N, Odawara M, Hori M, Hiraki Y, et al.
Biol Pharm Bull
. 2021 Oct;
44(10):1413-1418.
PMID: 34602550
The triplet antiemetic regimen is administered to prevent chemotherapy-induced nausea and vomiting (CINV) after moderately emetogenic chemotherapy (MEC). However, the superiority of palonosetron over first-generation 5-hydroxytryptamine-3 receptor antagonists in triplet...
3.
Hiramatsu A, Izumi Y, Eguchi K, Matsuo N, Deng Q, Inoue H, et al.
Hypertension
. 2021 Oct;
78(5):1335-1346.
PMID: 34601973
[Figure: see text].
4.
Eguchi K, Izumi Y, Yasuoka Y, Nakagawa T, Ono M, Maruyama K, et al.
J Endocrinol
. 2021 Mar;
249(2):95-112.
PMID: 33705345
Rhesus C glycoprotein (Rhcg), an ammonia transporter, is a key molecule in urinary acid excretion and is expressed mainly in the intercalated cells (ICs) of the renal collecting duct. In...
5.
Matsuo N, Maruta M, Tsuruyama M, Nagano M, Fujimoto Y, Yamashina T, et al.
Yakugaku Zasshi
. 2020 Mar;
140(3):449-453.
PMID: 32115568
Herein, we investigated the pharmacokinetic (PK) profile of nedaplatin (cis-diamine-glycolateplatinum; CDGP) in a hemodialysis (HD) patient with advanced esophageal squamous cell carcinoma (ESCC) by administering the CDGP immediately prior to...
6.
Maruta M, Miyoshi T, Matsuo N, Yamashina T, Irie K, Tsuruta M, et al.
J Chemother
. 2020 Feb;
33(1):51-55.
PMID: 32066346
We administered FOLFOX (oxaliplatin (L-OHP) plus infusional 5-fluorouracil (5-FU) and leucovorin) to an hemodialysis (HD) patient with advanced gastric cancer (AGC), and investigated pharmacokinetics (PKs) and dialyzability of L-OHP. The...
7.
Eguchi K, Izumi Y, Nakayama Y, Inoue H, Marume T, Matsuo N, et al.
Nephrology (Carlton)
. 2018 Dec;
24(11):1131-1141.
PMID: 30582257
Aim: Metabolic acidosis occurs due to insufficient urinary ammonium excretion as chronic kidney disease (CKD) advances. Because obese subjects tend to have excessive consumption of protein and sodium chloride, they...
8.
Tsuruta M, Miyoshi T, Tsuruyama M, Matsumoto S, Yamashina T, Irie K, et al.
J Palliat Med
. 2018 Mar;
21(5):598-603.
PMID: 29565714
Background: The skin fixative used in Mohs chemosurgery contains zinc chloride and is referred to as Mohs paste (MP). However, MP shows a remarkable change in rheological characteristics after its...
9.
Izumi Y, Inoue H, Nakayama Y, Eguchi K, Yasuoka Y, Matsuo N, et al.
PLoS One
. 2017 Sep;
12(8):e0184185.
PMID: 28859164
Metabolic acidosis often results from chronic kidney disease; in turn, metabolic acidosis accelerates the progression of kidney injury. The mechanisms for how acidosis facilitates kidney injury are not fully understood....
10.
Oguri Y, Fujita Y, Abudukadier A, Ohashi A, Goto T, Furuya F, et al.
JCI Insight
. 2017 May;
2(9.
PMID: 28469071
Brown adipose tissue (BAT) is a central organ that acts to increase energy expenditure; its regulatory factors could be clinically useful in the treatment of obesity. Tetrahydrobiopterin (BH4) is an...